Holen Sie sich die Stockscreener-App
19.82
2.57%
0.3845
Schlusskurs vom Vortag:
$19.44
Offen:
$19.482
24-Stunden-Volumen:
646.46K
Relative Volume:
0.74
Marktkapitalisierung:
$1.47B
Einnahmen:
$97.36M
Nettoeinkommen (Verlust:
$-172.42M
KGV:
-8.6253
EPS:
-2.2984
Netto-Cashflow:
$-188.84M
1W Leistung:
+6.01%
1M Leistung:
+32.49%
6M Leistung:
+51.40%
1J Leistung:
+115.80%
1-Tages-Spanne:
$19.46
$20.60
1-Wochen-Bereich:
$18.80
$21.26
52-Wochen-Spanne:
$6.92
$21.26
Xencor Inc Stock (XNCR) Company Profile
Firmenname
Xencor Inc
Sektor
Branche
Telefon
626-305-5900
Adresse
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
19.81 | 1.44B | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
479.62 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
669.65 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.70 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.47 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
280.84 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-10-29 | Hochstufung | Barclays | Underweight → Overweight |
| 2025-09-17 | Fortgesetzt | Barclays | Underweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2024-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Bestätigt | BTIG Research | Buy |
| 2024-02-28 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Eingeleitet | BofA Securities | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-10-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-21 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-02-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2020-02-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-01-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-08-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-04-12 | Eingeleitet | Guggenheim | Buy |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Neutral |
| 2017-03-02 | Bestätigt | Wedbush | Outperform |
| 2016-10-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-12-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-05 | Bestätigt | MLV & Co | Buy |
| 2015-02-12 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-28 | Bestätigt | MLV & Co | Buy |
| 2014-07-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Xencor Inc Aktie (XNCR) Neueste Nachrichten
Xencor Inc (XNCR) Income Statement - TradingKey
Xencor Inc (XNCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xencor Inc (XNCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xencor Inc (XNCR) Balance Sheet - TradingKey
Xencor Inc (XNCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ETFs Investing in Xencor, Inc. Stocks - TradingView
Xencor, Inc. Revenue Breakdown – DUS:XE9 - TradingView
Xencor Inc (XNCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo! Finance Canada
Xencor (NASDAQ:XNCR) Stock Price Down 6.7%Should You Sell? - MarketBeat
(XNCR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Xencor (NASDAQ:XNCR) Hits A High: Can Momentum Last? - Kalkine Media
Xencor stock hits 52-week high at 18.83 USD - Investing.com India
Xencor (NASDAQ:XNCR) Sets New 52-Week HighShould You Buy? - MarketBeat
Xencor (NASDAQ:XNCR) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Xencor stock hits 52-week high at 18.83 USD By Investing.com - Investing.com UK
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Xencor Shares Kidney Cancer Trial Results at ESMO - t.co
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma - BioSpace
Xencor shows strong pipeline progress with prom... - Pluang
Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data - Seeking Alpha
Xencor (XNCR) Shares Jump 17% Following ESMO 2026 Announcement - GuruFocus
Xencor (NASDAQ:XNCR) Stock Price Up 7.9%What's Next? - MarketBeat
Xencor’s XmAb819 data to be presented at ESMO congress By Investing.com - Investing.com South Africa
Xencor’s XmAb819 data to be presented at ESMO congress - Investing.com
Xencor to present Phase 1 XmAb819 data in advanced kidney cancer at ESMO 2026 - Bitget
Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus - The National Law Review
Xencor: Bullish On Their Increasingly In-House Pipeline (NASDAQ:XNCR) - Seeking Alpha
Xencor (NASDAQ:XNCR) Shares Down 6.6%Should You Sell? - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xencor Inc. (XNCR) Faces Pressure as Shares Slide Toward Key SupportQuality Factor - dars.gov.et
Form 4 Xencor Inc For: 8 July By Investing.com - Investing.com Nigeria
Ellen Feigal at Xencor (XNCR) receives RSUs and options equity awards - Stock Titan
Xencor (XNCR) awards RSUs and stock options to director Gorman - Stock Titan
Xencor (XNCR) director Kurt Gustafson granted RSUs and stock options - Stock Titan
[Form 4] Xencor Inc Insider Trading Activity - Stock Titan
Xencor (XNCR) director granted RSUs and stock options in equity award - Stock Titan
Xencor (XNCR) director granted RSUs and 20,604 stock options at $12.20 - Stock Titan
Xencor (NASDAQ: XNCR) awards director stock grants vesting within a year - Stock Titan
Xencor (NASDAQ: XNCR) director receives new RSU and stock option grant - Stock Titan
Frontier tech research, news & data - MLQ.ai
Truist Financial Maintains Xencor(XNCR.US) With Buy Rating, Cuts Target Price to $27 - Moomoo
XENCOR Maintains Buy Rating -- Price Target Lowered to $27.00 by Truist Securities - GuruFocus
XNCRXencor Inc Revenue Breakdown - Finviz
Xencor (XNCR) Declines 4.5% as Selling Pressure Builds Near SupportTurnaround Stocks - dars.gov.et
Enterprise value to revenue forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Price to earnings forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Enterprise value to EBIT forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Price to sales forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Price to sales forward of Xencor, Inc. – TRADEGATE:XE9 - TradingView
Xencor (XNCR) Surges Over 6% as Biotech Sector Momentum Drives Shares Toward Key ResistanceInsider Selling Alerts - dars.gov.et
Finanzdaten der Xencor Inc-Aktie (XNCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):